Timing of Corticosteroids in Non-severe Non-hospitalized COVID-19 Patients: Open-label, Two-center, Randomized Controlled Study (TICS-COV19 Study)

Overview

Journal Korean J Intern Med

Specialty General Medicine

Date 2023 Jan 16

PMID 36646988

Authors

Emad R Issak

Mariam M Amin

Affiliations

Soon will be listed here.

Abstract

Background/aims: Corticosteroids (CSs) are frequently used in coronavirus disease 2019 (COVID-19); however, their utility remains controversial in mild to moderate cases. The timing of CSs initiation during the disease course remains unaddressed. The study aims to evaluate the impact of early CSs in non-severe COVID-19.

Methods: A randomized controlled, open-label study was conducted on 754 COVID-19 patients randomized into a study group (n = 377) in which patients received CSs with COVID-19 protocol and a control group (n = 377) in which patients received COVID-19 protocol only.

Results: Both groups were comparable regarding baseline characteristics, presenting symptoms, and inflammatory markers. The composite endpoint (need for O2, need for hospitalization or 28-day mortality) was significantly (p = 0.004) lower in the CS group 42 (11.14%) versus the control group 70 (18.67%) with odds ratio 0.55 (95% confidence interval [CI], 0.36 to 0.83), absolute risk reduction 7.53% (95% CI, 2.46% to 12.59%) and number needed to treat of 13.29 (95% CI, 7.94 to 40.61). Regarding severity at day 10, only (11.1%) of the study group patients were severe versus (18.7%) of the control group patients (p < 0.001). The median time-to-return to daily activity in the CS group was 8.0 days, while in the control group, it was 22.0 days (p < 0.001).

Conclusion: In non-severe COVID-19, CS may decrease hospitalization, severity, and mortality.

Citing Articles

The impact of dexamethasone on short- and long-term mortality in hospitalized COVID-19 patients: a retrospective study.

Zhao J, Jiang H, Wan H, Liu D, Zhao Y, Chen Y BMC Infect Dis. 2024; 24(1):1343.

PMID: 39587481 PMC: 11590211. DOI: 10.1186/s12879-024-10216-3.

Prevalence and Outcomes of Candida auris Infections in a Tertiary Hospital in the United Arab Emirates (UAE).

Subhi A, Alshamsi S, Vitus A, Harazeen A Cureus. 2024; 16(9):e69988.

PMID: 39445294 PMC: 11497757. DOI: 10.7759/cureus.69988.

The Efficacy of Oral/Intravenous Corticosteroid Use in COVID-19 Patients: A Systematic Review.

Latarissa I, Rendrayani F, Iftinan G, Suhandi C, Meiliana A, Sormin I J Exp Pharmacol. 2024; 16:321-337.

PMID: 39371262 PMC: 11453156. DOI: 10.2147/JEP.S484596.

Corticosteroids for non-severe COVID-19 infections? Too early to conclude.

Park S Korean J Intern Med. 2023; 38(2):144-146.

PMID: 36864598 PMC: 9993106. DOI: 10.3904/kjim.2023.046.

References

Lee N, Chan K, Hui D, Ng E, Wu A, Chiu R . Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004; 31(4):304-9. PMC: 7108318. DOI: 10.1016/j.jcv.2004.07.006. View

Yu L, Bafadhel M, Dorward J, Hayward G, Saville B, Gbinigie O . Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021; 398(10303):843-855. PMC: 8354567. DOI: 10.1016/S0140-6736(21)01744-X. View

Tang X, Feng Y, Ni J, Zhang J, Liu L, Hu K . Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial. Respiration. 2021; 100(2):116-126. PMC: 7900459. DOI: 10.1159/000512063. View

Spagnuolo V, Guffanti M, Galli L, Poli A, Querini P, Ripa M . Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19. Sci Rep. 2020; 10(1):21291. PMC: 7718220. DOI: 10.1038/s41598-020-78039-1. View

Salvi R, Patankar P . Emerging pharmacotherapies for COVID-19. Biomed Pharmacother. 2020; 128:110267. PMC: 7221369. DOI: 10.1016/j.biopha.2020.110267. View

Russell B, Moss C, Rigg A, Van Hemelrijck M . COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?. Ecancermedicalscience. 2020; 14:1023. PMC: 7105332. DOI: 10.3332/ecancer.2020.1023. View

Ranjbar K, Moghadami M, Mirahmadizadeh A, Fallahi M, Khaloo V, Shahriarirad R . Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 2021; 21(1):337. PMC: 8035859. DOI: 10.1186/s12879-021-06045-3. View

Yuan M, Xu X, Xia D, Tao Z, Yin W, Tan W . Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis. Shock. 2020; 54(5):638-643. DOI: 10.1097/SHK.0000000000001574. View

Han Y, Jiang M, Xia D, He L, Lv X, Liao X . COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster. Clin Immunol. 2020; 214:108413. PMC: 7139268. DOI: 10.1016/j.clim.2020.108413. View

10.

Li Q, Li W, Jin Y, Xu W, Huang C, Li L . Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study. Infect Dis Ther. 2020; 9(4):823-836. PMC: 7467137. DOI: 10.1007/s40121-020-00332-3. View

11.

Fadel R, Morrison A, Vahia A, Smith Z, Chaudhry Z, Bhargava P . Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19. Clin Infect Dis. 2020; 71(16):2114-2120. PMC: 7314133. DOI: 10.1093/cid/ciaa601. View

12.

Tang C, Wang Y, Lv H, Guan Z, Gu J . Caution against corticosteroid-based COVID-19 treatment. Lancet. 2020; 395(10239):1759-1760. PMC: 7247780. DOI: 10.1016/S0140-6736(20)30749-2. View

13.

Meduri G, Siemieniuk R, Ness R, Seyler S . Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS. J Intensive Care. 2018; 6:53. PMC: 6109298. DOI: 10.1186/s40560-018-0321-9. View

14.

Almas T, Ehtesham M, Khan A, Khedro T, Hussain S, Kaneez M . Safety and Efficacy of Low-Dose Corticosteroids in Patients With Non-severe Coronavirus Disease 2019: A Retrospective Cohort Study. Cureus. 2021; 13(1):e12544. PMC: 7863064. DOI: 10.7759/cureus.12544. View

15.

Siddiqi H, Mehra M . COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020; 39(5):405-407. PMC: 7118652. DOI: 10.1016/j.healun.2020.03.012. View

16.

Annane D, Pastores S, Arlt W, Balk R, Beishuizen A, Briegel J . Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Intensive Care Med. 2017; 43(12):1781-1792. DOI: 10.1007/s00134-017-4914-x. View

17.

Ling Y, Xu S, Lin Y, Tian D, Zhu Z, Dai F . Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl). 2020; 133(9):1039-1043. PMC: 7147278. DOI: 10.1097/CM9.0000000000000774. View

18.

Arabi Y, Mandourah Y, Al-Hameed F, Sindi A, Almekhlafi G, Hussein M . Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2017; 197(6):757-767. DOI: 10.1164/rccm.201706-1172OC. View

19.

Li H, Chen C, Hu F, Wang J, Zhao Q, Gale R . Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia. 2020; 34(6):1503-1511. PMC: 7199650. DOI: 10.1038/s41375-020-0848-3. View

20.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View